Literature DB >> 33578545

Exosome as potential biomarkers for gastrointestinal tumors.

Jinlong Zhang1, Shudan Fu, Wenshuo Chen, Haijin Chen.   

Abstract

INTRODUCTION: Exosomes are polyvesicles that are formed by invagination of intracellular lysosomal particles, and are released into the extracellular matrix after the fusion of polyvesicular outer membrane and cell membrane. In the body, immune response, antigen presentation, cell migration, cell differentiation and tumor invasion are closely related to tumorigenesis and tumor progression. This study aimed to conduct a meta-analysis for evaluating the clinicopathological, diagnostic and prognostic significance of exosomal expression in gastrointestinal tumors.
METHODS: The original English articles were systematically searched in the online databases. The diagnostic accuracy, prognostic utility and clinicopathological correlation of gastrointestinal tumors were investigated. The quality assessment for studies of diagnostic accuracy II and Newcastle-Ottawa scale were used for quality evaluation, and the data was strictly extracted to judge the deviation of the study.
RESULTS: A total of 14 studies with 1837 gastrointestinal tumor patients were included. The change in exosomal expression showed significant correlation with poor clinicopathological parameters (tumor diameter: combined P = .00024394; differentiation: combined P = 2.796e-08; lymphatic metastasis: P = 9.610e-07; distant metastasis: combined P = .00017326; pathological classification: combined P = .00875213; invasion depth: combined P = 3.504e-08) carcinoembryonic antigen (combined P = . 04458857) and tumor location (combined P = .00145983). The difference in the area under the curve between gastrointestinal tumor patients and healthy people showed an area under the curve of 0.89 (95%Cl 0.85-0.91) and heterogeneity of 0.59, 95% CI=[0.55-0.68]. The sensitivity was 0.88 (95%Cl 0.83 mi 0.91), the specificity was 0.72 (95%Cl 0.63 mi 0.80), and the diagnostic odds ratio was 18 (10-33). The results of survival analysis revealed that the abnormally expressed exosomes were significantly correlated with poor overall survival (hazard ratio =2.81, 95% CI: 2.02-3.93, P=0.013∗ 62.7%∗).
CONCLUSION: The abnormally expressed exosomes might act as auxiliary biomarkers in diagnosing gastrointestinal tumors and demonstrated good prognostic significance in predicting the survival of patients with gastrointestinal tumors.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33578545      PMCID: PMC7886441          DOI: 10.1097/MD.0000000000024509

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  26 in total

1.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.

Authors:  Andreas Stang
Journal:  Eur J Epidemiol       Date:  2010-07-22       Impact factor: 8.082

2.  Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement.

Authors:  Matthew D F McInnes; David Moher; Brett D Thombs; Trevor A McGrath; Patrick M Bossuyt; Tammy Clifford; Jérémie F Cohen; Jonathan J Deeks; Constantine Gatsonis; Lotty Hooft; Harriet A Hunt; Christopher J Hyde; Daniël A Korevaar; Mariska M G Leeflang; Petra Macaskill; Johannes B Reitsma; Rachel Rodin; Anne W S Rutjes; Jean-Paul Salameh; Adrienne Stevens; Yemisi Takwoingi; Marcello Tonelli; Laura Weeks; Penny Whiting; Brian H Willis
Journal:  JAMA       Date:  2018-01-23       Impact factor: 56.272

Review 3.  The biology and function of exosomes in cancer.

Authors:  Raghu Kalluri
Journal:  J Clin Invest       Date:  2016-04-01       Impact factor: 14.808

4.  Exosomal long noncoding RNA CRNDE-h as a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer.

Authors:  Tong Liu; Xin Zhang; Shanyu Gao; Fangmiao Jing; Yongmei Yang; Lutao Du; Guixi Zheng; Peilong Li; Chen Li; Chuanxin Wang
Journal:  Oncotarget       Date:  2016-12-20

5.  Circulating exosomal miR-125a-3p as a novel biomarker for early-stage colon cancer.

Authors:  Jing Wang; Feihu Yan; Qi Zhao; Fei Zhan; Ruitao Wang; Liang Wang; Yanqiao Zhang; Xiaoyi Huang
Journal:  Sci Rep       Date:  2017-06-23       Impact factor: 4.379

6.  GPC1 exosome and its regulatory miRNAs are specific markers for the detection and target therapy of colorectal cancer.

Authors:  Jian Li; Yuxiang Chen; Xiong Guo; Lin Zhou; Zeming Jia; Zha Peng; Yaping Tang; Weidong Liu; Bin Zhu; Lei Wang; Caiping Ren
Journal:  J Cell Mol Med       Date:  2017-02-24       Impact factor: 5.310

7.  Tumor-derived exosomal miRNA-320d as a biomarker for metastatic colorectal cancer.

Authors:  Youyong Tang; Yajing Zhao; Xingguo Song; Xianrang Song; Limin Niu; Li Xie
Journal:  J Clin Lab Anal       Date:  2019-08-16       Impact factor: 2.352

8.  A pair-wise meta-analysis highlights circular RNAs as potential biomarkers for colorectal cancer.

Authors:  Chen Li; Xinli He; Lele Zhang; Lanying Li; Wenzhao Zhao
Journal:  BMC Cancer       Date:  2019-10-15       Impact factor: 4.430

9.  Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer.

Authors:  T Matsumura; K Sugimachi; H Iinuma; Y Takahashi; J Kurashige; G Sawada; M Ueda; R Uchi; H Ueo; Y Takano; Y Shinden; H Eguchi; H Yamamoto; Y Doki; M Mori; T Ochiya; K Mimori
Journal:  Br J Cancer       Date:  2015-06-09       Impact factor: 7.640

10.  Clinico-pathological significance of exosome marker CD63 expression on cancer cells and stromal cells in gastric cancer.

Authors:  Yuichiro Miki; Masakazu Yashiro; Tomohisa Okuno; Kenji Kuroda; Shingo Togano; Kosei Hirakawa; Masaichi Ohira
Journal:  PLoS One       Date:  2018-09-17       Impact factor: 3.240

View more
  1 in total

Review 1.  Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics.

Authors:  Anna D Louie; Kelsey Huntington; Lindsey Carlsen; Lanlan Zhou; Wafik S El-Deiry
Journal:  Front Pharmacol       Date:  2021-10-19       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.